$heff's $tation of $tocks & $olid DD

[ash111]

ONTX 2.7 reminder,End-of-Phase 2 meeting with FDA and European authorities relating oral rigosertib in combination with azacitidine expected to take place anytime- 2H2016. June 13, 2016 interim Data from Fully-Enrolled Phase 2 Trial, "23 of 30 patients, or 77%, responded to treatment, and anticipate further updates to the data set," stated Steve Fruchtman, M.D., Chief Medical Officer of Onconova. "Of note, 84% of HMA-naïve patients responded to this novel combination"
http://investor.onconova.com/releasedetail.cfm?ReleaseID=975436

$3m+ investment at 4.1 PPS just 2 month ago(a half of current market cap) is more than just a bet,imo:
Cash/share= 4.38 (27.6m / 6.3m o/s ), float is 3.3m due to past month buys by both funds+insiders http://insidertrading.org/index.php?sort_by=transaction_total_value&asc=1&symbol=ONTX&date_from=2016-08-10&date_to=2016-08-23&submit=+GO+

more catalysts/events this year.